Table of Contents Author Guidelines Submit a Manuscript
Advances in Hematology
Volume 2010, Article ID 137608, 7 pages
http://dx.doi.org/10.1155/2010/137608
Case Report

Promyelocytic Sarcoma of the Spine: A Case Report and Review of the Literature

1Hematology and BMT Unit, Institute of Hematotherapy, Ospedale S. Camillo, 00153 Rome, Italy
2Department of Biopathology, Tor Vergata University, 00133 Rome, Italy

Received 5 August 2009; Accepted 15 January 2010

Academic Editor: Stefan Faderl

Copyright © 2010 Leonardo Pacilli et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Myeloid sarcoma (MS, previously named granulocytic sarcoma or chloroma) is a rare extramedullary tumour of immature myeloid cells. It can be present before, concurrently with, or after the diagnosis of acute myeloid leukemia. MS is extremely uncommon in acute promyelocytic leukemia (APL). In the case described here, MS was the sole site of APL relapse and the cause of spinal cord compression. The patient presented with neurologic symptoms due to a paravertebral mass of MS after 7 years of complete remission. He was treated with excision of the mass followed by local radiotherapy. Systemic treatment was also given with combined arsenic trioxide and all-trans retinoic acid and the patient was able to achieve a second prolonged clinical and molecular remission.

1. Introduction

Myeloid sarcoma (MS, previously named granulocytic sarcoma or chloroma) is a rare extramedullary tumour of immature myeloid cells [1]. It can occur in association with myelogenous leukemia, myeloproliferative disorders, and myelodysplasia. MS has different modalities of presentation and can affect any organ. It may occur otherwise in healthy individuals who subsequently develop an overt typical myelogenous leukemia [1, 2]. MS can also develop in leukemia patients concurrently with or after diagnosis, or as a manifestation of disease relapse [3, 4]. The WHO recognizes three major variants of MS based on the predominant cell type and the degree of maturation, namely respectly, a myeloblast variant, with a mix of myeloblasts and promyelocytes variant, and more differentiated variant with promyelocytes and more mature granulocytes [5]. Acute promyelocytic leukemia (APL) accounts for approximately 10% of acute myeloid leukemia (AML) and cases of MS due to APL have been only occasionally reported [14]. We report the case of a patient with APL who presented right paraparesis after 7 years of complete remission. The patient had a MS with paravertebral localization as the only site of APL relapse.

2. Case Report

In November 1999, a 38-year-old male presented with a history of recurrent episodes of gum bleeding. Physical examination was unremarkable, but a complete blood count showed Hb 6.1 g/dL, WBC , and platelets . Microscopic examination of a blood smear showed 8% hypergranular promyelocytes, with Auer rods. At examination of bone marrow aspirate a diffuse infiltration by atypical promyelocytes was apparent. The immunophenotype profile of leukemic cells was consistent with APL (CD33+ve, CD45+ve, HLA-DR-ve, CD34-ve, CD16-ve, and CD56-ve). Cytogenetics revealed the characteristic t(15;17) (q22;q21-q22) and the RT-PCR assay showed the typical PML/RAR fusion gene thereby confirming the diagnosis of APL [6]. The patient was treated with all-trans retinoic acid (ATRA) 45 mg /m²/day ber 30 days and idarubicin (IDA) 12 mg/m²/day on days 2, 4, 6, and 8. On day 20, the patient had severe pulmonary distress that was consistent with an ATRA syndrome [7]. This was successfully managed with high-dose dexamethasone and ATRA discontinuation. Despite that, following induction, bone marrow evaluation revealed a morphologic and molecular picture of complete remission. The patient received 3 additional courses of chemotherapy as consolidation and completed his treatment in July 2002. Five years later in July 2007, the patient presented with right chest pain and progressive right paraparesis in a few-week duration. An MRI of the spine revealed a solid extramedullary intraspinal mass extending between T6 and T8. Diagnostic workup including coagulation profile and complete blood counts was normal, and neither atypical promyelocytes nor blast cells were detected in peripheral blood and bone marrow. In addition, PCR analysis for PML/RAR transcripted on bone marrow cells confirmed a status of molecular remission. Cord decompression was performed with total laminectomy and excision of an extradural soft tissue mass of 4 cm 5 cm 5 cm. Histopathology examination showed diffuse infiltration by monomorphic, medium-sized, neoplastic cells with round shaped deeply indented or bilobated nuclei with dispersed chromatin, inconspicuous nucleoli, and basophilic cytoplasm. The immunophenotype characteristics of neoplastic cells were as follows: myeloperoxidase and CD117 (c-KIT) were strongly positive; CD45 was weakly and focally expressed while CD34, CD31, CD20, CD79a, CD3, CD56, and CD15 were negative. Cytogenetic studies showed (Figure 1) t(15;17) (q22;q21-q22) with PML/RAR fusion gene as demonstrated by FISH LSI with PML/RAR probe dual color (Dual fusion translocation probe, Vysis/Abbot). Since the disease was localized to the spine, the patient underwent a local radiotherapy with 36 Gy.

137608.fig.001
Figure 1: (a) The pictures show adipose and fibrous tissue with dense and diffuse infiltrate of monomorphic PML cells ( , 20 ). (b) FISH revealed the presence of the reciprocal and balanced t(15;17) on PML cells (arrow).

Systemic therapy was also started on an outpatient basis with combined ATRA and arsenic trioxide (ATO) for a total of 5-month cycles according to the scheme reported by Estey et al. [8]. The patient were able to achieve and maintain a second complete hematologic remission. Currently, he is still in remission and well 20 months since the end of treatment.

3. Discussion

Extramedullary disease (EMD) at diagnosis or at relapse develops in 3%–8% of patients with acute myelogenous leukemia, more frequently in those with myelomonocytic and monocytic morphology [911] (M4 and M5 French- American- British subtypes). Its occurrence in APL is relatively rare but after the advent of ATRA it is increasingly reported at time of relapse [1129]. The case reported here, is a rare case of CNS isolated relapse [13]. The patient presented with neurologic symptoms due to a paravertebral mass after 7 years of complete remission. He entered a second prolonged clinical and molecular remission after local radiotherapy followed by a combination of ATRA and ATO. This case represents the second report of MS resulting in spinal cord compression due to APL extramedullary relapse. The other case, reported by Tsimberidou et al. [30], was a man who remained in complete remission for 3 years after treatment of APL. This patient later developed paraplegia due to a paravertebral mass at the level of T7-T8. Following decompression laminectomy, an isolated extramedullary promyelocytic relapse was diagnosed. The bone marrow was not involved. The patient was treated with local radiotherapy followed by ATRA and idarubicin, achieving a short second remission. He subsequently developed a second relapse with marrow and skin involvement.

The occurrence of EMD has long been considered a rare event in APL patients treated with chemotherapy alone, whereas this phenomenon has increasingly been reported in the ATRA era [5, 9, 38]. The question arises as to whether treatment of APL with ATRA predisposes patients to the development of EMD [38, 51]. This question is still open, as various trials have shown contrasting results. Wiernik et al. [3] suggested that extramedullary APL occurs more frequently after ATRA than other therapies. Ko et al. [23] demonstrated that patients receiving ATRA induction had a 2.1 increased relative risk of EMD compared with those with chemotherapy alone. In a literature review by Bae et al. [51], only three of 21 cases with CNS relapse received systemic chemotherapy without ATRA. Among 172 patients with APL treated at MDACC between 1980 and 2003, a total of three patients relapsed with isolated EMD and it occurred exclusively in patients who had received ATRA-containing induction regimens [51]. Ohno et al. [52] noted that EM relapse was absent from all 37 patients with relapsing APL in the Japanese chemotherapy only studies, while it was seen in 8% of 121 patients in the chemotherapy plus ATRA protocols and this raised the possibility that the doses of chemotherapy given with ATRA-based regimens are less intensive than those previously used and thus may not reach therapeutic levels in the EM tissues. This could be particularly relevant to protocols without cytarabine. A relationship between EMD and ATRA treatment has been suggested. Two possible explanations are considered. The first suggests a direct effect of ATRA on adhesion molecules resulting in increased infiltration capability of APL leukemia blasts [23]. The second postulates the occurrence of MS in relapsed patients as a consequence of the prolonged survival [38]. In a study of the GIMEMA [38], the authors found no statistical difference in the frequency of extramedullary involvement between patients treated with or without ATRA. EMD was documented in 5% and 12% of patients included in the LAP0389 and AIDA protocol, respectively, with no statistical difference. In particular, the five EMD localizations in the LAP0389 study were in the CNS (1 patient), the skin (3 patients), and the middle ear (1 patient). Of the 16 EMD relapses in the AIDA study, 10 involved the CNS and six involved other extramedullary sites (the skin in 3, the middle ear in 2, and the lung in 1). Thus CNS disease at relapse seems frequent among the AIDA treated patients (8% versus 1%) [39]. Breccia et al. [50] described three adult patients with middle ear localizations at relapse. They had been previously treated with ATRA and CT. Their characteristics are shown in Table 1.

tab1
Table 1: Clinical features of patients with MS in APL.

Similarly, C. Samanez et al. [53] reported 7 cases of EMD relapse in APL patients receiving chemotherapy (CT) alone (102 patients) or combined with ATRA (155 patients). EMD relapse rate was 4.4% in the CT group and 8.7% in the group CT plus ATRA, with no statistical differences. EMD localizations were in soft tissues (3 patients), the CNS (2 patients), the tonsils (1 patient), liver (1 patient), and the testis (1 patient). De Botton et al. [54] analyzed EMD relapse occurring in patients with APL treated with ATRA and CT. Of 740 patients included in three multicenter trials (APL91, APL93 trials, and PETHEMA 96) 10 patients developed EMD relapse. Of these, 9 were in the CNS and one in the skin. Only two patients had isolated EMD relapses. A significant correlation could be found between high WBC count and the risk of CNS relapse. More recently, Casanova et al. [55] reported a similar pattern of increased CNS EMD relapse in APL patients treated with ATRA and CT. EMD relapse was found in 8 of 74 (15%) APL patients (CNS: 5, external ear: 3). Together, these studies confirm that the CNS is the preferential site of extramedullary involvement in APL, raising an issue of whether or not to consider CNS prophylaxis in APL treatment protocols especially in patients presenting with hyperleukocytosis, as suggested by the expert panel of the European Leukemia Net. However, the benefit of this policy has not been established in prospective studies [56].The occurrence of the ATRA syndrome was recognized to be a significant risk factor for EMD involvement at relapse [57]. Since APL cells, in patients affected by ATRA syndrome, infiltrate multiple tissues and organs, including the lung and the skin, it was hypothesized that ATRA could promote the migration of differentiating blasts into the skin, the CNS, and other tissues which represented a reservoir of viable blasts. These cells could later proliferate and result in an EMD recurrence [9, 11, 23, 27, 57]. Others have found that elevated WBC count (  L) on presentation [55], predominance of the PML/RAR bcr3 type, and mirogranular morphology [50] are considered as risk factors.

Management of relapse in the CNS and other extramedullary sites in patients with APL is a challenging issue for which there is a notable lack of information. EMD relapse, including in the CNS, can occur either in isolation or associated with BM involvement as a first relapse, and also after one or more hematologic relapses. Optimal management and outcome of APL patients in these different situations have not been critically assessed. In case of granulocytic sarcoma, wherever it is localized, radiation and intensive systemic therapy might be considered.

Before the demonstration of the striking activity of ATO in APL, salvage therapy usually consisted of the readministration of ATRA and chemotherapy for induction, generally containing high-dose cytarabine and an anthracycline, followed by further chemotherapy and/or hematopoietic stem cell transplantation (HSCT) [5860]. Confirmation of the high and sustained efficacy of ATO in patients with relapsed/refractory APL has been provided by more recent studies [61, 62]. CR rates in these trials were 80%–90% and, in those studies that evaluated survival, 50%–70% of patients were alive at 1 for 3 years. Current evidence suggests that the use of at least 2 cycles of ATO results in the achievement of second molecular CR in nearly 80% of cases [63]. The best consolidation strategy after ATO induced second remission is unknown; options include continued treatment with repeated cycles of ATO, the use of standard chemotherapy in combination with ATRA and/or ATO, and HSCT. For patients unfit to proceed to HSCT, the available options include repeated cycles of ATO with or without ATRA/standard chemotherapy.

The central nervous system (CNS) is the commonest site of extramedullary disease in APL and at least 10% of hematologic relapses are accompanied by CNS involvement [11]. Because the majority of CNS relapses occur in patients presenting with hyperleukocytosis some strategies include CNS prophylaxis for patients in this particular high-risk setting. For such patients, it is advisable to postpone CNS prophylaxis until after the achievement of CR because lumbar puncture at presentation and during induction is extremely hazardous. However, the benefit of this policy has not been established. For patients without hyperleukocytosis, in whom the risk of CNS relapse is extremely low, there is a general consensus to avoid CNS prophylaxis.

CNS prophylaxis for patients in this particular high-risk setting. For such patients, it is advisable to postpone CNS prophylaxis until after the achievement of CR because lumbar puncture at presentation and during induction is extremely hazardous. However, the benefit of this policy has not been established. For patients without hyperleukocytosis, in whom the risk of CNS relapse is extremely low, there is a general consensus to avoid CNS prophylaxis.

In conclusion, the increasing number and special pattern of EMD involvement in relapsing APL patients emphasize its importance in the differential diagnosis of EMD localization in patients with history of APL. they also highlight the need for understanding the underlying pathogenesis and predisposing factors, as well as for selecting the optimal treatment approach.

References

  1. R. S. Neiman, M. Barcos, C. Berard et al., “Granulocytic sarcoma: a clinicopathologic study of 61 biopsied cases,” Cancer, vol. 48, no. 6, pp. 1426–1437, 1981. View at Google Scholar · View at Scopus
  2. L. P. Menasce, S. S. Banerjee, E. Beckett, and M. Harris, “Extra-medullary myeloid tumour (granulocytic sarcoma) is often misdiagnosed: a study of 26 cases,” Histopathology, vol. 34, no. 5, pp. 391–398, 1999. View at Publisher · View at Google Scholar · View at Scopus
  3. P. H. Wiernik, R. De Bellis, P. Muxi, and J. P. Dutcher, “Extramedullary acute promyelocytic leukemia,” Cancer, vol. 78, p. 25, 1996. View at Google Scholar
  4. M. Benekli, M. C. Savas, I. C. Haznedaroglu, and S. V. Dündar, “Granulocytic sarcoma in acute promyelocytic leukemia,” Leukemia and Lymphoma, vol. 22, no. 1-2, pp. 183–185, 1996. View at Google Scholar · View at Scopus
  5. E. S. Jaffe, N. L. Harris, H. Stein, and J. W. Vardimann, Eds., World Health Organisation Classification of Tumours—Tumours of Haematopoietic and Lymphoid Tissues, vol. 105, IARC Press, London, UK, 2001.
  6. P. Fenaux, C. Chomienne, and L. Degos, “Acute promyelocytic leukemia: biology and treatment,” Seminars in Oncology, vol. 24, no. 1, pp. 92–102, 1997. View at Google Scholar · View at Scopus
  7. R. S. Larson and M. S. Tallman, “Retinoic acid syndrome: manifestations, pathogenesis, and treatment,” Best Practice and Research: Clinical Haematology, vol. 16, no. 3, pp. 453–461, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. E. Estey, G. Garcia-Manero, A. Ferrajoli et al., “Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia,” Blood, vol. 107, no. 9, pp. 3469–3473, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. V. Liso, G. Specchia, E. M. Pogliani et al., “Extramedullary involvement in patients with acute promyelocytic leukemia: a report of seven cases,” Cancer, vol. 83, no. 8, pp. 1522–1528, 1998. View at Google Scholar
  10. A.-M. Tsimberidou, H. M. Kantarjian, E. Estey et al., “Outcome in patients with nonleukemic granulocytic sarcoma treated with chemotherapy with or without radiotherapy,” Leukemia, vol. 17, no. 6, pp. 1100–1103, 2003. View at Publisher · View at Google Scholar · View at PubMed
  11. G. D. Evans and D. J. Grimwade, “Extramedullary disease is acute promyelocytic leukemia,” Leukemia and Lymphoma, vol. 33, no. 3-4, pp. 219–229, 1999. View at Google Scholar
  12. L. Degos, “All-trans retinoic acid (ATRA) therapeutical effect in acute promyelocytic leukemia,” Biomedicine and Pharmacotherapy, vol. 46, no. 5–7, pp. 201–209, 1992. View at Google Scholar
  13. Y. Kanakura, T. Yonezawa, Y. Hamaguchi et al., “Acute promyelocytic leukemia with an intracerebral mass and meningeal involvement after treatment of non-Hodgkin's lymphoma,” Cancer, vol. 59, no. 1, pp. 94–98, 1987. View at Google Scholar · View at Scopus
  14. R. Marra, S. Stori, L. Pagano et al., “Central nervous system acute promyelocytic leukaemia: a report of three cases,” Haematologia, vol. 22, no. 3, pp. 195–199, 1989. View at Google Scholar · View at Scopus
  15. Z. Niazi, P. Molt, A. Mittelman, Z. A. Arlin, and T. Ahmed, “Leukemic dermal infiltrates at permanent indwelling central venous catheter insertion sites,” Cancer, vol. 68, no. 10, pp. 2281–2283, 1991. View at Google Scholar · View at Scopus
  16. M. R. Baer, M. Barcos, H. Farrell, A. Raza, and H. D. Preisler, “Acute myelogenous leukemia with leukemia cutis. eighteen cases seen between 1969 and 1986,” Cancer, vol. 63, no. 11, pp. 2192–2200, 1989. View at Google Scholar · View at Scopus
  17. T. A. Longacre and B. R. Smoller, “Leukemia cutis: analysis of 50 biopsy-proven cases with an emphasis on occurrence in myelodysplastic syndromes,” American Journal of Clinical Pathology, vol. 100, no. 3, pp. 276–284, 1993. View at Google Scholar · View at Scopus
  18. S. Giralt, S. O'Brien, E. Weeks, M. Luna, and H. Kantarjian, “Leukemia cutis in acute promyelocytic leukemia: report of three cases after treatment with all-trans retinoic acid,” Leukemia and Lymphoma, vol. 14, no. 5-6, pp. 453–456, 1994. View at Google Scholar · View at Scopus
  19. G. Evans, D. Grimwade, H. G. Prentice, and N. Simpson, “Central nervous system relapse in acute promyelocytic leukaemia in patients treated with all-trans retinoic acid,” British Journal of Haematology, vol. 98, no. 2, pp. 437–439, 1997. View at Google Scholar · View at Scopus
  20. A. Menendez, A. Gonzales, H. Cabrera et al., “Clinical spectrum of extramedullary acute promyelocytic leukemia,” European Journal of Haematology, vol. 64, no. 3, pp. 201–203, 2000. View at Publisher · View at Google Scholar · View at Scopus
  21. J. C. Byrd and R. B. Weiss, “Recurrent granulocytic sarcoma: an unusual variation of acute myelogenous leukemia associated with 8;21 chromosomal translocation and blast expression of the neural cell adhesion molecule,” Cancer, vol. 73, no. 8, pp. 2107–2112, 1994. View at Google Scholar · View at Scopus
  22. L. D. Burry and J. T. Seki, “CNS relapses of acute promyelocytic leukemia after all-trans retinoic acid,” Annals of Pharmacotherapy, vol. 36, no. 12, pp. 1900–1906, 2002. View at Google Scholar · View at Scopus
  23. B.-S. Ko, J.-L. Tang, Y.-C. Chen et al., “Extramedullary relapse after all-trans retinoic acid treatment in acute promyelocytic leukemia—the occurrence of retinoic acid syndrome is a risk factor,” Leukemia, vol. 13, no. 9, pp. 1406–1408, 1999. View at Google Scholar · View at Scopus
  24. K. Yamauchi and M. Yasuda, “Comparison in treatments of nonleukemic granulocytic sarcoma: report of two cases and a review of 72 cases in the literature,” Cancer, vol. 94, no. 6, pp. 1739–1746, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  25. J. R. Mesa, E. Espinosa, R. Losada, C. Hernandez, G. Martinez, and P. Hernandez, “Parotid and central nervous system relapse during complete hematologic remission in acute promyelocytic leukemia,” Haematologica, vol. 84, no. 6, pp. 565–566, 1999. View at Google Scholar · View at Scopus
  26. M. Seldon and A. Enno, “Central nervous system relapse in acute promyelocytic leukaemia treated with all-trans retinoic acid,” Australian and New Zealand Journal of Medicine, vol. 28, no. 4, p. 462, 1998. View at Google Scholar
  27. M. A. Weiss and R. P. Warrell Jr., “Two cases of extramedullary acute promyelocytic leukemia: cytogenetics, molecular biology, and phenotypic and clinical studies,” Cancer, vol. 74, no. 7, pp. 1882–1886, 1994. View at Google Scholar · View at Scopus
  28. G. Milone, G. Inghilterra, F. Li Gioi et al., “Testicular and cutaneous relapse after hematopoietic transplantation in a patient affected with APL,” Bone Marrow Transplantation, vol. 23, no. 7, p. 751, 1999. View at Google Scholar
  29. T. Kai, H. Kimura, Y. Shiga, K. Ogawa, H. Sato, and Y. Maruyama, “Recurrent extramedullary relapse of acute promyelocytic leukemia after allogeneic stem cell transplantation: successful treatment by arsenic trioxide in combination with local radiotherapy,” International Journal of Hematology, vol. 83, no. 4, pp. 337–340, 2006. View at Publisher · View at Google Scholar · View at PubMed
  30. A. M. Tsimberidou, E. Estey, G. J. Whitman et al., “Extramedullary relapse in a patient with acute promyelocytic leukemia: successful treatment with arsenic trioxide,all-trans retinoic acid and gemtuzumab ozogamicin therapies,” Leukemia Research, vol. 28, pp. 991–994, 2004. View at Google Scholar
  31. S. Fukushima, M. Terasaki, Y. Tajima, and M. Shigemori, “Granulocytic sarcoma: an unusual complication of acute promyelocytic leukemia causing cerebellar hemorrhage. Case report,” Journal of Neurosurgery, vol. 105, no. 6, pp. 912–915, 2006. View at Publisher · View at Google Scholar · View at PubMed
  32. J. Worch, J. Ritter, and M. C. Frühwald, “Presentation of acute promyelocytic leukemia as granulocytic sarcoma,” Pediatric Blood and Cancer, vol. 50, no. 3, pp. 657–660, 2008. View at Publisher · View at Google Scholar · View at PubMed
  33. D. S. S. Ajarim, C. R. Santhosh-Kumar, K. E. Higgy, N. S. El Saghir, A. K. Al-Momen, and F. D. Shipkey, “Granulocytic sarcoma of the thymus in acute promyelocytic leukaemia,” Clinical and Laboratory Haematology, vol. 12, no. 1, pp. 97–99, 1990. View at Google Scholar
  34. A. Savranlar, Y. Ustündag, T. Ozer et al., “A thoracic-epidural granulocytic sarcoma case that was diagnosed preceding the onset of and that recurred co-incidental to acute promyelocytic leukemia, which developed after surgical treatment,” Acta Medica Okayama, vol. 58, no. 5, pp. 251–254, 2004. View at Google Scholar
  35. D. M. Brown, A. E. Kimura, K. C. Ossoinig, and G. J. Weiner, “Acute promyelocytic infiltration of the optic nerve treated by oral trans-retinoic acid,” Ophthalmology, vol. 99, no. 9, pp. 1463–1467, 1992. View at Google Scholar
  36. N. Agarwal, E. M. Tepe, A. Mishra, and J. H. Ward, “Relapse of acute promyelocytic leukemia presenting as granulocytic sarcoma in the hip,” Annals of Hematology, vol. 85, no. 10, pp. 741–742, 2006. View at Publisher · View at Google Scholar · View at PubMed
  37. U. Disel, S. Yavuz, S. Paydas, B. Sahin, and H. Zeren, “Extramedullary relapse in the pleura in acute promyelocytic leukemia,” Leukemia and Lymphoma, vol. 44, no. 1, pp. 189–191, 2003. View at Publisher · View at Google Scholar
  38. G. Specchia, F. Lo Coco, M. Vignetti et al., “Extramedullary involvement at relapse in acute promyelocytic leukemia patients treated or not with all-trans retinoic acid: a report by the Gruppo Italiano Malattie Ematologiche dell'Adulto,” Journal of Clinical Oncology, vol. 19, no. 20, pp. 4023–4028, 2001. View at Google Scholar
  39. R. Latagliata, I. Carmosino, M. Breccia et al., “Late relapses in acute promyelocytic leukaemia,” Acta Haematologica, vol. 117, no. 2, pp. 106–108, 2007. View at Publisher · View at Google Scholar · View at PubMed
  40. M. A. Sanz, L. Larrea, G. F. Sanz et al., “Cutaneous promyelocytic sarcoma at sites of vascular access and marrow aspiration. A characteristic localization of chloromas in acute promyelocytic leukaemia,” Haematologica, vol. 85, pp. 758–762, 2000. View at Google Scholar
  41. G. Magliulo, M. Fusconi, and G. Pulice, “Acute promyelocytic leukemia and aural recurrence: the importance of otoscopy in early diagnosis,” Leukemia, vol. 17, no. 7, pp. 1418–1419, 2003. View at Publisher · View at Google Scholar · View at PubMed
  42. B. Nasilowska-Adamska, M. Majewski, I. Seferynska et al., “Predictive value of RT-PCR PML-RARA transcript monitoring for extramedullary relapse of acute promyelocytic leukemia in the pleura, heart and pericardium after allogeneic SCT,” Annals of Transplantation, vol. 12, no. 3, pp. 33–38, 2007. View at Google Scholar
  43. V. Slavcheva, T. Lukanov, and N. Tzvetkov, “Two cases of extramedullary myeloid tumor in patients with continuous remission of acute myeloblastic leukemia,” Journal of BUON, vol. 13, no. 4, pp. 589–592, 2008. View at Google Scholar
  44. T. Kai, H. Kimura, Y. Shiga, K. Ogawa, H. Sato, and Y. Maruyama, “Recurrent extramedullary relapse of acute promyelocytic leukemia after allogeneic stem cell transplantation: successful treatment by arsenic trioxide in combination with local radiotherapy,” International Journal of Hematology, vol. 83, no. 4, pp. 337–340, 2006. View at Publisher · View at Google Scholar · View at PubMed
  45. T. Tobita, K. Shinjyo, M. Yanagi, A. Takeshita, K. Ohnishi, and R. Ohno, “Relapse in the external auditory canal of acute promyelocytic leukemia after treatment with all-trans retinoic acid,” Internal Medicine, vol. 36, no. 7, pp. 484–486, 1997. View at Google Scholar
  46. D. L. Forrest, B. I. Dalal, S. C. Naiman et al., “Testicular relapse of acute promyelocytic leukemia after allogeneic BMT,” Bone Marrow Transplantation, vol. 20, no. 8, pp. 689–690, 1997. View at Google Scholar
  47. A. Skarin, S. K. Ma, C. Ooi et al., “CNS extramedullary relapse of acute promyelocytic leukemia after arsenic trioxide—induced remission,” Journal of Clinical Oncology, vol. 18, pp. 3435–3437, 2000. View at Google Scholar
  48. F. Leoni, G. Gianfaldoni, M. Annunziata et al., “Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: a bridge to transplantation,” Haematologica, vol. 87, no. 5, pp. 485–489, 2002. View at Google Scholar
  49. E. Ammatuna, P. A. Borza, A. P. Iori et al., “Multiple relapses and extramedullary localization with scalp and breast involvement in a case of acute promyelocytic leukemia,” Leukemia, vol. 19, no. 3, pp. 479–480, 2005. View at Publisher · View at Google Scholar · View at PubMed
  50. M. Breccia, M. C. Petti, A. M. Testi et al., “Ear involvement in acute promyelocytic leukemia at relapse: a disease associated ‘sanctuary’?” Leukemia, vol. 16, no. 6, pp. 1127–1130, 2002. View at Publisher · View at Google Scholar
  51. S. H. Bae, H. M. Ryoo, H. S. Cho, J. L. Lee, K. H. Lee, and M. S. Hyun, “Meningeal relapse in a patient with acute promyelocytic leukemia: a case report and review of the literature,” Journal of Korean Medical Science, vol. 19, no. 2, pp. 311–314, 2004. View at Google Scholar
  52. R. Ohno, N. Asou, and K. Ohnishi, “Treatment of acute promyelocytic leukemia: strategy toward further increase of cure rate,” Leukemia, vol. 17, no. 8, pp. 1454–1463, 2003. View at Publisher · View at Google Scholar · View at PubMed
  53. C. Samanez, S. Santillana, J. Leon, A. Wachtel, C. Vallejos, and Instituto de Enfermedades Neoplasicas, Lima, Peru, “Pattern of extramedullary relapse in acute promyelocytic leukemia (APL) in Peruvian patients,” in Proceedings of the Annual Meeting of American Society of Clinical Oncology (ASCO '02), vol. 21, 2002, abstract no. 1090.
  54. S. de Botton, M. A. Sanz, S. Chevret et al., “Extramedullary relapse in acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy,” Leukemia, vol. 20, no. 1, pp. 35–41, 2006. View at Publisher · View at Google Scholar · View at PubMed
  55. L. A. Casanova, S. M. Quintana, S. P. Neciosup, and C. A. Samanez, “Pattern of extramedullary relapse in latin patients with acute promyelocytic leukemia (APL) treated with all-trans-retinoic acid (ATRA) and chemotherapy,” in Proceedings of the Annual Meeting of American Society of Clinical Oncology (ASCO '07), vol. 25, p. 18S, 2007, abstract no. 1752.
  56. M. A. Sanz, D. Grimwade, M. S. Tallman et al., “Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet,” Blood, vol. 113, no. 9, pp. 1875–1891, 2009. View at Publisher · View at Google Scholar · View at PubMed
  57. F. Patriarca, C. Fili, A. Geromin, A. Sperotto, S. Prosdocimo, and R. Fanin, “Activity of all-trans-retinoic acid in a case of central nervous system extramedullary relapse of acute promyelocytic leukemia,” European Journal of Haematology, vol. 68, no. 5, pp. 310–313, 2002. View at Publisher · View at Google Scholar · View at Scopus
  58. J. Esteve, L. Escoda, G. Martín et al., “Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-trans retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99): benefit of an early intervention,” Leukemia, vol. 21, no. 3, pp. 446–452, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  59. E. H. Estey, “Treatment options for relapsed acute promyelocytic leukaemia,” Best Practice and Research: Clinical Haematology, vol. 16, no. 3, pp. 521–534, 2003. View at Publisher · View at Google Scholar · View at Scopus
  60. X. Thomas, H. Dombret, C. Cordonnier et al., “Treatment of relapsing acute promyelocytic leukemia by all-trans retinoic acid therapy followed by timed sequential chemotherapy and stem cell transplantation,” Leukemia, vol. 14, no. 6, pp. 1006–1013, 2000. View at Google Scholar · View at Scopus
  61. W. Y. Au, A. K. W. Lie, C. S. Chim et al., “Arsenic trioxide in comparison with chemotherapy and bone marrow transplantation for the treatment of relapsed acute promyelocytic leukaemia,” Annals of Oncology, vol. 14, no. 5, pp. 752–757, 2003. View at Publisher · View at Google Scholar · View at Scopus
  62. K. Shigeno, K. Naito, N. Sahara et al., “Arsenic trioxide therapy in relapsed or refractory Japanese patients with acute promyelocytic leukemia: updated outcomes of the phase II study and postremission therapies,” International Journal of Hematology, vol. 82, no. 3, pp. 224–229, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  63. M. S. Tallman, “Treatment of relapsed or refractory acute promyelocytic leukemia,” Best Practice and Research in Clinical Haematology, vol. 20, no. 1, pp. 57–65, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus